Journal
EXPERIMENTAL NEUROLOGY
Volume 213, Issue 1, Pages 122-128Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2008.05.011
Keywords
ammonium tetrathiomolybdate; amyotrophic lateral sclerosis; copper; copper/zinc superoxide dismutase; cysteine residue
Categories
Funding
- Frontier Project for the College of Pharmacy, Nihon University
Ask authors/readers for more resources
Mutations in copper/zinc superoxide dismutase (SOD1) cause a form of familial amyotrophic lateral sclerosis (ALS). The pathogenesis of familial ALS may be associated with aberrant copper chemistry through a cysteine residue ill Mutant SOD1. Ammonium tetrathiomolybdaLe (TTM) is a copper-chelating drug that is capable of removing a copper ion from copper-thiolate Clusters, Such as SOD1. We found that TTM exerted therapeutic benefits in a mouse model of familial ALS (SOD1(G93A)). TTM treatment significantly delayed disease onset, slowed disease Progression and prolonged survival by approximately 20%, 42% and 25%, respectively. TTM also effectively depressed the spinal copper ion level and inhibited lipid peroxidation, with a significant Suppression of SOD1 enzymatic activity in SOD1(G93A). These results support the hypothesis that aberrant copper chemistry through a cysteine residue plays a critical role in mutant SOD1 toxicity and that TTM may be a promising therapy for familial ALS with SOD1 Mutants. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available